123 results about "Th polarization" patented technology

The invention provides for a composition comprising a genetically engineered bacteriophage capable of guiding cell growth and polarization via signaling peptides and directionally aligned structures. The invention provides for modified bacteriophage and its uses thereof. The present invention also provides for genetically engineered phage capable of guiding cell growth, migration and/or alignment, providing essential biological effects including proliferation and/or differentiation, which can be performed by expressing specific biological motifs, such as the amino acid sequences RGD, IKVAV, DGEA and HPQ, on their coat proteins, on which functional DNA, proteins and cells can be conjugated and/or fixed thereon.

The invention provides a macrophage exclusive chimeric antigen receptor, a controllable polarized mononuclear/macrophage for expressing the macrophage exclusive chimeric antigen receptor, and a preparation method and application thereof, and relates to the field of biotechnology. The invention provides a chimeric antigen receptor which comprises an extracellular antigen binding domain, a transmembrane domain and an intracellular activation domain which are sequentially connected, and the extracellular antigen binding domain comprises signal peptide and/or scFv and can specifically recognize cell membrane surface protein EGFRvIII specifically expressed by GBM; the transmembrane domain comprises CD8alpha which linking the extracellular antigen binding domain and the intracellular activation domain; an intracellular activation domain comprises TIR, CD3ZETA or GM-CSFRalpha/beta and promotes polarization of macrophages to M1, the chimeric antigen receptor is introduced into the macrophages, the macrophages are endowed with a targeted killing effect on GBM, and the M1 polarization state of the macrophages is effectively promoted and maintained.

The invention provides type 1 polarized dendritic cells and an inducing method and application thereof. A novel DC1 preparation method is built through the assistant function of Natural Killer cells of umbilical cord blood in the adaptive immunity activating process of DCs, and in the preparation process, usage of cell factors is reduced, the cost is lowered, and quality control is improved. The invention further provides a method for applying the prepared DC1s to preparation of CTLs with the tumor antigen specificity; after the DC1s are loaded with tumor specific antigens, part of the cells are transfused to a patient body, the other part of the cells are used for in-vitro inductive cytotoxic T lymphocytes (CTL) with the tumor antigen specificity, and the immunoreaction of the tumor specificity is activated through the mode of combining active induction with passive induction in vivo and vitro.

The invention discloses a method for efficiently and sequentially inducing macrophages to be polarized in vitro. The method comprises the following steps of: S1, carrying out multiplication culture onTHP-1 cells by using an RPMI1640 culture medium containing 10% of FBS and beta-mercaptoethanol; S2, carrying out pretreatment before induction on the THP-1 cells by using PBS containing HPL and a culture medium; S3, in an RPMI1640 culture medium which contains 5% of HPL and does not contain the beta-mercaptoethanol, slowly inducing the THP-1 cells by adopting low-concentration PMA so as to enablethe THP1 cells to be differentiated into M0 macrophages in an adherence mode, and then removing the PMA; and S4, in an RPMI1640 culture medium which contains 5% of HPL and does not contain the beta-mercaptoethanol, inducing M0 macrophages for more than 72 hours by using LPS/IFN-gamma, so that the M0 macrophages are polarized into M1; or inducing the M0 macrophages for more than 72 hours by usingIL-4/IL-13, so that the M0 macrophages are polarized into M2 macrophages. Compared with the prior art, the method disclosed by the invention has the advantages that firstly, the THP-1 cells are slowlyinduced by adopting the low-concentration PMA, so that the immatureness state of the M0 type macrophages differentiated from the THP1 cells can be guaranteed; and then the optimal induced polarization time of the subsequent M1/M2 type macrophages is over 72 hours, so that the polarization state of the M1/M2 type macrophages is guaranteed. Meanwhile, the differentiation process is carried out in an environment without animal-derived components, so that the polarization efficiency of the macrophages can be effectively ensured.

The present invention provides several modified ABC transporter polypeptides that exhibit novel localization in the plasma membrane of polarized and non-polarized cells. The modified ABC transporter of the invention comprises the amino acid sequence of a native apically targeted ABC transporter, in particular cMOAT, MDR3 or MRP4, wherein the terminal tripeptide T-K-F motif of said native ABC transporter is mutated. The isolated modified ABC transporter polypeptide of the invention, and the nucleotide sequence encoding said polypeptide, have utility in the following applications: First, they are used to induce a drug resistant phenotype in a cell. Second, they are used to protect non-polarized cells during chemotherapy and other therapeutic applications. Third, they are used to produce novel cell lines that are used to screen for novel agonists or antagonists of the corresponding native ABC transporter polypeptides.

The invention relates to the technical field of biological medicines and particularly discloses a method for adjusting a polarization state of a macrophage. The method comprises the step of adopting an over-expressed HIMF gene to infect the macrophage or adopting specific siRNA to knock down or integrally knock out an HIMF gene in the macrophage. Through the mode, the macrophage is infected by adopting the over-expressed HIMF gene or the HIMF gene in the macrophage is knocked down or integrally knocked out by adopting the specific siRNA, and functions of macrophages of different polarization types are influenced, so that the occurrence and development of inflammations are inhibited, and the occurrence of myocardial infarction is delayed.

The present invention relates to intraductal methods and compositions for treating subjects having breast disorders. Compositions comprise repolarizing agents and polarization blockading agents capable of repolarizing M2-macrophages to M1-macrophages in the tumor microenvironment, decreasing M2-macrophages, increasing M1-macrophages and/or increasing sensitivity to chemotherapy in the subject.

The invention discloses a medium and method for proliferation and differentiation of alveolus organoids. The method disclosed by the invention can reliably obtain the human alveolus organoids with relatively low cost and relatively high efficiency, and is beneficial to large-scale popularization and use of the alveolus organoids in the biomedical industry. The alveolus organoids related to the invention can remedy all the defects of a traditional alveolar in-vitro model at present, thereby meeting the four basic requirements of an alveolus disease model: (1) the alveolus organoids have the capabilities of sustained proliferation and sustained differentiation; (2) a complete tissue structure (monolayer polarized cystic epithelium) and normal physiological functions (for example secretion ofan alveolus surfactant, an alveolus innate immune process and the like) of alveoli in vivo can be retained or reproduced; (3) the alveolus organoids have good operability, and can be repeated cryopreserved, resuscitated and passaged like a cell line; and (4) the alveolus organoids come from human tissue and reflect individual differences.

The invention provides a method for regulating the polarization state of macrophages. The method comprises the step of activating cholinergic anti-inflammatory pathways of the macrophages by adoptingcholinergic anti-inflammatory pathway agonists and/or vagus nerve electrical stimulation signals. According to the method in the invention, the cholinergic anti-inflammatory pathway agonists are adopted to stimulate the macrophages in vitro; or the electrical stimulation signals are adopted to stimulate vagus nerves in vivo; therefore, the cholinergic anti-inflammatory pathways are activated; polarization of M1 type macrophages is inhibited; polarization of M2 type macrophages is promoted; a regulating effect on macrophage polarization types is achieved; and the method has the important significance in the aspects of specifically regulating the functions of the polarized macrophages and diseases caused by the polarized macrophages.

The invention provides a method for efficiently preparing DC1 cells through T cell culture medium supernatant. Peripheral blood of tumor patients or healthy people is processed, immature DC cells are separated out, and a product where DC1 cells are enriched is obtained through oriented induction. The product prepared in this way has the capacity for efficiently inducing tumor specific CTL cells and Th1 cells, and can be used for optimizing the clinical effect of the tumor immunity treatment technology. In addition, the invention further provides a method for using the prepared DC1 cells for preparing tumor antigen specific CTL cells. After the DC1 cells are loaded with tumor specific antigens, one part of the DC1 cells are conveyed back into patient bodies, the other part of the DC1 cells are used for in-vitro tumor antigen specific induction cytotoxic lymphocytes (CTL), and the specific immune reaction of tumors is activated through an in-vivo/in-vitro and active induction/passive induction combined mode.

A biostimulator, such as a leadless pacemaker, having electrode(s) coated with low-polarization coating(s), is described. A low-polarization coating including titanium nitride can be disposed on an anode, and a low-polarization coating including a first layer of titanium nitride and a second layer of platinum black can be disposed on a cathode. The anode can be an attachment feature used to transmit torque to the biostimulator. The cathode can be a fixation element used to affix the biostimulator to a target tissue. The low-polarization coating(s) impart low-polarization to the electrode(s) to enable an atrial evoked response to be detected and used to effect automatic output regulation of the biostimulator. Other embodiments are also described and claimed.

The application provides use of a CSF-1R kinase inhibitor, i.e., a compound with a general formula (A) or pharmaceutically acceptable salts thereof in preparation of drugs for treating CSF-1R kinase signal transduction channel related diseases or drugs for regulating immunity. Shown by in-vivo and in-vitro researches, the compound can be used for remarkably inhibiting the activity of a CSF-1R kinase; the compound can be used for remarkably inhibiting proliferation of a CSF-1/CSF-1R-driven mouse myeloid leukemia cell line, inhibiting survival of CSF-1-induced macrophages and reversing M2-leant polarization phenotypes of the macrophages, and the effect is superior to that of a drug Pexidartinib on the market; in a TAMs-enriched tumor model (MC38 model), the compound can be used for remarkably antagonizing a tumor immunity inhibiting microenvironment, and a remarkable antitumor drug effect is embodied; and the compound has an inhibiting action on tumors insensitive to immunity check point drugs, can be used for strengthening the treatment effect of the immunity check point drugs and has a very good clinical application prospect.

The invention discloses a molecular docking method based on a polarizable bond model. The method is characterized in that on the basis of traditional molecular docking, polarizable bonds contained inthe ligands are recognized according to a protein environment where ligands are located and charges are updated; then molecular docking is conducted again (the updated charges are forcibly used); andthe operation is repeated till energy is converged, and the optimal binding mode is obtained. Compared with the prior art, the method has the advantages that the polarization effect of EPB charges isenhanced, the intermolecular hydrogen bond interaction is enhanced, the molecular docking precision is effectively improved; and the method is more efficient than a QM/MM equivalent molecular dockingmethod.